Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial.
Journal article
Strauss KA. et al, (2022), Nature medicine
Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial.
Journal article
Strauss KA. et al, (2022), Nature medicine
Financial cost and quality of life of patients with spinal muscular atrophy identified by symptoms or newborn screening.
Journal article
Dangouloff T. et al, (2022), Dev Med Child Neurol
Onasemnogene abeparvovec for the treatment of spinal muscular atrophy.
Journal article
McMillan HJ. et al, (2022), Expert Opin Biol Ther
Risdiplam: an investigational motor neuron-2 (SMN-2) splicing modifier for spinal muscular atrophy (SMA).
Journal article
Markati T. et al, (2022), Expert opinion on investigational drugs
Respiratory management of spinal muscular atrophy type 1 patients treated with Nusinersen.
Journal article
Menard J. et al, (2022), Pediatric pulmonology
Real-world and natural history data for drug evaluation in Duchenne muscular dystrophy: suitability of the North Star Ambulatory Assessment for comparisons with external controls.
Journal article
Muntoni F. et al, (2022), Neuromuscul Disord
Response of plasma microRNAs to nusinersen treatment in patients with SMA
Journal article
Zaharieva IT. et al, (2022), Annals of Clinical and Translational Neurology
Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial.
Journal article
Mercuri E. et al, (2022), Lancet Neurol, 21, 42 - 52
Stride Velocity 95th Centile: Insights into Gaining Regulatory Qualification of the First Wearable-Derived Digital Endpoint for use in Duchenne Muscular Dystrophy Trials.
Journal article
Servais L. et al, (2021), J Neuromuscul Dis
Hierarchical Bayesian modelling of disease progression to inform clinical trial design in centronuclear myopathy
Journal article
Fouarge E. et al, (2021), Orphanet Journal of Rare Diseases, 16
The administration of antisense oligonucleotide golodirsen reduces pathological regeneration in patients with Duchenne muscular dystrophy
Journal article
Scaglioni D. et al, (2021), Acta Neuropathologica Communications, 9
Long-Term Safety and Efficacy Data of Golodirsen in Ambulatory Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-in-human, Multicenter, Two-Part, Open-Label, Phase 1/2 Trial.
Journal article
Servais L. et al, (2021), Nucleic Acid Ther
Home-based gait analysis as an exploratory endpoint during a multicenter phase 1 trial in limb girdle muscular dystrophy type R2 and facioscapulohumeral muscular dystrophy.
Journal article
Gidaro T. et al, (2021), Muscle Nerve
Three years pilot of spinal muscular atrophy newborn screening turned into official program in Southern Belgium.
Journal article
Boemer F. et al, (2021), Sci Rep, 11
Genotype-related respiratory progression in Duchenne Muscular Dystrophy - multicentre international study.
Journal article
Trucco F. et al, (2021), Muscle Nerve
Crowdfunding for neuromuscular disease treatment: the ethical implications.
Journal article
Livingstone A. et al, (2021), Lancet Neurol, 20, 788 - 789
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial.
Journal article
Mercuri E. et al, (2021), Lancet Neurol, 20, 832 - 841
Upper limb disease evolution in exon 53 skipping eligible patients with Duchenne muscular dystrophy.
Journal article
Lilien C. et al, (2021), Ann Clin Transl Neurol
First Regulatory Qualification of a Novel Digital Endpoint in Duchenne Muscular Dystrophy: A Multi-Stakeholder Perspective on the Impact for Patients and for Drug Development in Neuromuscular Diseases
Journal article
Servais L. et al, (2021), Digital Biomarkers, 5, 183 - 190